search
Back to results

HORMA: Hormonal Regulators of Muscle and Metabolism in Aging

Primary Purpose

Sarcopenia, Muscle Weakness, Frailty

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Topical testosterone
Recombinant human growth hormone
Sponsored by
National Institute on Aging (NIA)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sarcopenia focused on measuring andropause, hormone therapy, HRT

Eligibility Criteria

65 Years - 90 Years (Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria: Men who are 65-90 years of age Total serum IGF-1 (insulin-like growth factor) in the lower tertile for adults (56-167 ug/dl) Total serum testosterone of 150-550 ng/dL Exclusion Criteria: BMI (Body Mass Index) 35 kg/m2 or greater Weight instability (>3% change in prior 3 months) Daily intake of total kilocalories less than or equal to 0.8X the RDA and intake of protein between 0.8 and 1.4 g/kg/day inclusive Acute illness in the prior 30 days Resistance training (wt lifting) in the past 12 months Vigorous aerobic sports (Competing as a Master athlete in the prior 5 years; weekly swimming, racquet ball, cycling, tennis, in preceding 12 months) Use of an anabolic agent (androgen, androgen precursor, rhGH, etc) in the preceding 12 months Use of medications that might affect amino acid metabolism (e.g. beta-adrenergic blockers, beta-agonists, Ca2+ channel blockers, corticosteroids) Fasting sugar greater than or equal to 126 mg/dl or diabetes requiring Rx History of benign intracranial hypertension Heart failure, active angina, or myocardial infarction in the prior 6 months or history of aortic stenosis Uncontrolled hypothyroidism or hyperthyroidism Rheumatoid arthritis, cirrhosis or active hepatitis History of carpal tunnel syndrome Prior cancer other than squamous or basal cell carcinoma of the skin Sleep apnea or severe chronic lung disease Anticoagulation with heparin or coumadin Blood pressure not controlled with medication to <180/95 mm Hg Calculated creatinine clearance <50 cc/min Serum prostatic antigen >4.0 or American Urological Association score greater than or equal to 8 Hematocrit greater than or equal 52%, or ALT >1.5X ULN Failure to pass a modified Bruce treadmill stress test Severe disability limiting strength or physical function testing Dementia or cognitive impairment affecting a subject's ability to provide informed consent

Sites / Locations

  • Tufts University
  • Washington University School of Medicine

Outcomes

Primary Outcome Measures

measures of fractional synthetic rates of mixed and contractile (actin and myosin heavy chain [MHC]) skeletal muscle proteins and degradation of skeletal muscle (ubiquitin, and proteasome sub-units)
analysis of local regulators of skeletal muscle synthesis (e.g. IGF-1, IGFBP4, myostatin).

Secondary Outcome Measures

change in skeletal muscle strength, muscle mass, power and fatigability (endurance), physical performance, and markers of safety.

Full Information

First Posted
September 13, 2005
Last Updated
May 28, 2009
Sponsor
National Institute on Aging (NIA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00183040
Brief Title
HORMA: Hormonal Regulators of Muscle and Metabolism in Aging
Official Title
Hormonal Regulators of Muscle and Metabolism in Aging
Study Type
Interventional

2. Study Status

Record Verification Date
May 2009
Overall Recruitment Status
Completed
Study Start Date
September 2002 (undefined)
Primary Completion Date
February 2007 (Actual)
Study Completion Date
February 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute on Aging (NIA)

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine the relationship of deficiencies in testosterone and growth hormone to loss of muscle mass (sarcopenia) and functional impairment during aging and whether there is an interaction of these two hormone systems in maintaining normal skeletal muscle mass and physical function.
Detailed Description
Elderly persons experience progressive loss of skeletal muscle mass, muscle strength, and functional capacity for activities of daily living. Aging is also associated with a loss of hormones believed to be related to muscle and strength, namely testosterone and growth hormone (GH). The hypothesis being tested is that both hormone systems regulate musculoskeletal protein mass and contractile fibers by different and complimentary mechanisms and that optimal levels of both testosterone and GH are necessary to maintain skeletal muscle mass, muscular strength and power, and full functional activities of daily living during the aging process. This is a controlled, 16 week study to evaluate the independent effects and interaction of these two anabolic hormone systems in community dwelling elderly men 65-90 years of age who are hyposomatotropic (deficiency of growth hormone) with low eugonadal status (total testosterone of 150-550 ng/dL). The study will utilize a two tiered randomization in which 108 study participants will first be randomized to either the low or high eugonadal level of testosterone using a novel Leydig cell clamp method (GnRH (gonadotropin-releasing hormone) agonist plus topical testosterone supplementation) to achieve target levels of testosterone. Low gonadal status (150-550 ng/dL) will be maintained with 5 g daily doses of topical testosterone, whereas high gonadal status (650-950 ng/dL) will be achieved with 10 g daily doses. Within these two groups, participants will be randomized to receive placebo or one of two doses of rhGH (recombinant human growth hormone) therapy (0, 3.0, 5.0 mcg/kg/day) in a double blinded fashion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcopenia, Muscle Weakness, Frailty
Keywords
andropause, hormone therapy, HRT

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
Double
Allocation
Randomized
Enrollment
108 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Topical testosterone
Intervention Type
Drug
Intervention Name(s)
Recombinant human growth hormone
Primary Outcome Measure Information:
Title
measures of fractional synthetic rates of mixed and contractile (actin and myosin heavy chain [MHC]) skeletal muscle proteins and degradation of skeletal muscle (ubiquitin, and proteasome sub-units)
Title
analysis of local regulators of skeletal muscle synthesis (e.g. IGF-1, IGFBP4, myostatin).
Secondary Outcome Measure Information:
Title
change in skeletal muscle strength, muscle mass, power and fatigability (endurance), physical performance, and markers of safety.

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
65 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men who are 65-90 years of age Total serum IGF-1 (insulin-like growth factor) in the lower tertile for adults (56-167 ug/dl) Total serum testosterone of 150-550 ng/dL Exclusion Criteria: BMI (Body Mass Index) 35 kg/m2 or greater Weight instability (>3% change in prior 3 months) Daily intake of total kilocalories less than or equal to 0.8X the RDA and intake of protein between 0.8 and 1.4 g/kg/day inclusive Acute illness in the prior 30 days Resistance training (wt lifting) in the past 12 months Vigorous aerobic sports (Competing as a Master athlete in the prior 5 years; weekly swimming, racquet ball, cycling, tennis, in preceding 12 months) Use of an anabolic agent (androgen, androgen precursor, rhGH, etc) in the preceding 12 months Use of medications that might affect amino acid metabolism (e.g. beta-adrenergic blockers, beta-agonists, Ca2+ channel blockers, corticosteroids) Fasting sugar greater than or equal to 126 mg/dl or diabetes requiring Rx History of benign intracranial hypertension Heart failure, active angina, or myocardial infarction in the prior 6 months or history of aortic stenosis Uncontrolled hypothyroidism or hyperthyroidism Rheumatoid arthritis, cirrhosis or active hepatitis History of carpal tunnel syndrome Prior cancer other than squamous or basal cell carcinoma of the skin Sleep apnea or severe chronic lung disease Anticoagulation with heparin or coumadin Blood pressure not controlled with medication to <180/95 mm Hg Calculated creatinine clearance <50 cc/min Serum prostatic antigen >4.0 or American Urological Association score greater than or equal to 8 Hematocrit greater than or equal 52%, or ALT >1.5X ULN Failure to pass a modified Bruce treadmill stress test Severe disability limiting strength or physical function testing Dementia or cognitive impairment affecting a subject's ability to provide informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fred R. Sattler, MD
Organizational Affiliation
Keck School of Medicine, University of Southern California
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tufts University
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02111
Country
United States
Facility Name
Washington University School of Medicine
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63108
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
9331374
Citation
Dutta C, Hadley EC, Lexell J. Sarcopenia and physical performance in old age: overview. Muscle Nerve Suppl. 1997;5:S5-9. No abstract available.
Results Reference
background
PubMed Identifier
10751194
Citation
Hasten DL, Pak-Loduca J, Obert KA, Yarasheski KE. Resistance exercise acutely increases MHC and mixed muscle protein synthesis rates in 78-84 and 23-32 yr olds. Am J Physiol Endocrinol Metab. 2000 Apr;278(4):E620-6. doi: 10.1152/ajpendo.2000.278.4.E620.
Results Reference
background
PubMed Identifier
7491931
Citation
Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995 Nov;269(5 Pt 1):E820-6. doi: 10.1152/ajpendo.1995.269.5.E820.
Results Reference
background
PubMed Identifier
11832363
Citation
Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E601-7. doi: 10.1152/ajpendo.00362.2001.
Results Reference
background
PubMed Identifier
12425705
Citation
Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, Jayme J, O'Connor KG, Christmas C, Tobin JD, Stewart KJ, Cottrell E, St Clair C, Pabst KM, Harman SM. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002 Nov 13;288(18):2282-92. doi: 10.1001/jama.288.18.2282.
Results Reference
background
PubMed Identifier
21543538
Citation
Yarasheski KE, Castaneda-Sceppa C, He J, Kawakubo M, Bhasin S, Binder EF, Schroeder ET, Roubenoff R, Azen SP, Sattler FR. Whole-body and muscle protein metabolism are not affected by acute deviations from habitual protein intake in older men: the Hormonal Regulators of Muscle and Metabolism in Aging (HORMA) Study. Am J Clin Nutr. 2011 Jul;94(1):172-81. doi: 10.3945/ajcn.110.010959. Epub 2011 May 4.
Results Reference
derived

Learn more about this trial

HORMA: Hormonal Regulators of Muscle and Metabolism in Aging

We'll reach out to this number within 24 hrs